Clinical trial · Interventional
Intralesional Acyclovir Versus Intralesional Zinc Sulphate in the Treatment of Plantar Warts
NCT07848100CI-TRIAL-00126703not yet recruitingPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 30, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260930-000001
Summary
Brief summary (as posted)
This clinical trial aims to compare the efficacy and safety of intralesional acyclovir versus intralesional zinc sulphate in the treatment of plantar warts.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Human Papillomavirus Infection | — | UNRESOLVED | — |
| Plantar Warts | — | UNRESOLVED | — |
| Skin Diseases, Viral | — | UNRESOLVED | — |
| Warts | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Intralesional Acyclovir | Drug | — | UNRESOLVED |
| Intralesional Zinc Sulphate | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Intralesional Acyclovir
- description
- This group will receive intralesional acyclovir
- interventionNames
- Drug: Intralesional Acyclovir
- type
- ACTIVE_COMPARATOR
- label
- Intralesional Zinc Sulphate
- description
- This group will receive intralesional zinc sulphate 2%
- interventionNames
- Drug: Intralesional Zinc Sulphate
Primary outcomes (1)
- measure
- Clinical Response of the Injected Warts
- timeFrame
- 8 weeks
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 50 Years
Show eligibility criteria text
Inclusion Criteria: * Patients aged 18-50 years of both sexes clinically diagnosed with multiple plantar warts. Exclusion Criteria: * Patients with wart types other than plantar warts (genital, common, and plane warts). * Pregnant or lactating women. * Immunocompromised patients. * Individuals receiving systemic immunosuppressive or antiviral therapy. * History of hypersensitivity to acyclovir or zinc compounds. * Patients with current acute febrile illness or any bacterial infection. * Receiving any treatment for warts within 1 month before the study. * Concurrent other skin disorders. * Patients with systemic diseases (liver or renal disease, bleeding disorders).
References
Publications (6)
- BACKGROUNDBarkat MT, Abdel-Aziz RTA, Mohamed MS. Evaluation of intralesional injection of bleomycin in the treatment of plantar warts: clinical and dermoscopic evaluation. Int J Dermatol. 2018 Dec;57(12):1533-1537. doi: 10.1111/ijd.14092. Epub 2018 Jun 15. PMID 29907964
- BACKGROUNDYoussef EMK, Eissa MAA, Bakr RM. Intralesional Candida albicans antigen versus intralesional zinc sulfate in treatment of cutaneous warts. Arch Dermatol Res. 2023 Jul;315(5):1305-1314. doi: 10.1007/s00403-022-02499-w. Epub 2022 Dec 26. PMID 36567351
- BACKGROUNDMohamed EE, Tawfik KM, Mahmoud AM. The Clinical Effectiveness of Intralesional Injection of 2% Zinc Sulfate Solution in the Treatment of Common Warts. Scientifica (Cairo). 2016;2016:1082979. doi: 10.1155/2016/1082979. Epub 2016 Mar 31. PMID 27123361
- BACKGROUNDGharib K, Taha A, Elradi M. Intralesional acyclovir versus intralesional Hepatitis-B vaccine in treatment of resistant plantar warts: a randomized controlled trial. Arch Dermatol Res. 2024 Jun 1;316(6):325. doi: 10.1007/s00403-024-03001-4. PMID 38822848
- BACKGROUNDMullen SA, Myers EL, Brenner RL, Nguyen KT, Harper TA, Welsh D, Keffer S, Mueller J, Whitley MJ. Systematic Review of Intralesional Therapies for Cutaneous Warts. JID Innov. 2024 Jan 24;4(3):100264. doi: 10.1016/j.xjidi.2024.100264. eCollection 2024 May. PMID 38585192
- BACKGROUNDAl Aboud AM, Nigam PK. Wart. 2023 Aug 14. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from http://www.ncbi.nlm.nih.gov/books/NBK431047/ PMID 28613701